Home > Insider Trading > Filing (0001209191-21-008101)

Filing Details

Accession Number:: 0001209191-21-008101
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-05 16:43:57
Reporting Period:: 2021-02-03

Accepted Time:: 2021-02-05 16:43:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557290	A Stuart Arbuckle	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Evp, Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-03	8,438	$0.00	43,617	No	4	A	Direct
Common Stock	Acquisiton	2021-02-03	12,388	$0.00	56,005	No	4	A	Direct
Common Stock	Acquisiton	2021-02-03	13,952	$0.00	69,957	No	4	A	Direct
Common Stock	Acquisiton	2021-02-03	1,554	$86.52	71,511	No	4	M	Direct
Common Stock	Disposition	2021-02-03	148	$211.22	71,363	No	4	S	Direct
Common Stock	Disposition	2021-02-03	488	$212.77	70,875	No	4	S	Direct
Common Stock	Disposition	2021-02-03	497	$213.90	70,378	No	4	S	Direct
Common Stock	Disposition	2021-02-03	242	$214.98	70,136	No	4	S	Direct
Common Stock	Disposition	2021-02-03	90	$215.80	70,046	No	4	S	Direct
Common Stock	Disposition	2021-02-03	89	$216.83	69,957	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-02-03	1,554	$0.00	1,554	$86.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2027-02-02	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	140	Indirect	401(k)

Footnotes

Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021.
Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021.
Restricted stock unit award that vests in installments beginning on 02/17/2022.
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $211.22 (range $211.06 to $211.27).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $212.77 (range $212.29 to $213.20).
Open market sales reported on this line occurred at a weighted average price of $213.90 (range $213.49 to $214.17).
Open market sales reported on this line occurred at a weighted average price of $214.98 (range $214.72 to $215.36).
Fully vested.